Headache News and Research

Latest Headache News and Research

Study finds no added benefit from sipuleucel-T in men with metastatic prostate cancer

Sipuleucel-T (trade name Provenge) has been approved since September 2014 for men with metastatic prostate cancer who have few or no symptoms and do not yet require chemotherapy. In the dossier assessment conducted by the German Institute for Quality and Efficiency in Health Care (IQWiG) in January 2015, no added benefit could be derived for sipuleucel-T.

22 Mar 2015

AAPM announces recipients of 2015 Pain Medicine Fellowship Excellence Award

The American Academy of Pain Medicine is pleased to announce its 2015 Pain Medicine Fellowship Excellence Award Recipients in recognition of a Pain Medicine Fellowship Program that provides an exceptional learning experience to its fellows, preparing them to deliver the highest standard of care to patients with pain.

22 Mar 2015

Cosentyx (secukinumab) safe, effective for treating psoriasis patients

Novartis today announced new two-year results demonstrating sustained efficacy with Cosentyx (secukinumab) with an acceptable safety profile for the treatment of psoriasis patients. The data comes from the extension study of the pivotal Phase III FIXTURE and ERASURE trials.

21 Mar 2015

Daiichi Sankyo signs co-commercialization agreement with AstraZeneca for MOVANTIK (naloxegol)

Daiichi Sankyo, Inc. today announced a co-commercialization agreement with AstraZeneca for MOVANTIK (naloxegol) in the US, in line with the Daiichi Sankyo strategy to expand its US portfolio through strategic alliances, in addition to internal R&D and acquisitions.

19 Mar 2015

Endo announces commercial availability of NATESTO nasal gel for men with hypogonadism

Endo Pharmaceuticals Inc., a subsidiary of Endo International plc (NASDAQ: ENDP) (TSX: ENL), announced today the commercial availability of NATESTO (testosterone nasal gel), the first and only nasal gel for testosterone replacement therapy in adult males diagnosed with hypogonadism.

16 Mar 2015

Egalet announces net revenues of $1.9 million for 2014

Egalet Corporation today reported financial results for the year ended December 31, 2014.

16 Mar 2015

Meta-analysis finds that high dose zinc acetate lozenges may help reduce duration of cold symptoms

According to a meta-analysis published in BMC Family Practice, high dose zinc acetate lozenges shortened the duration of common-cold associated nasal discharge by 34%, nasal congestion by 37%, scratchy throat by 33%, and cough by 46%.

16 Mar 2015

New device can detect cyanide exposure within 70 seconds

A victim of cyanide poisoning can die within 30 minutes. The diagnostic test to determine cyanide exposure takes 24 hours.

13 Mar 2015

FDA approves Astellas' CRESEMBA for treatment of invasive aspergillosis, invasive mucormycosis

Astellas today announced that the U.S. Food and Drug Administration has approved its New Drug Application (NDA) for the use of CRESEMBA (isavuconazonium sulfate), the prodrug for isavuconazole, for patients 18 years of age and older in the treatment of invasive aspergillosis and invasive mucormycosis (also known as zygomycosis).

8 Mar 2015

electroCore’s gammaCore device effective in helping patients prevent, treat cluster headache

A twelve-month open-label study in the March issue of the journal Neurology, reports that electroCore’s non-invasive Vagus Nerve stimulation (nVNS) device, gammaCore, is practical and effective as an acute and preventative treatment in cluster headache. Seventy-nine percent of patients who completed the trial (15 out of 19) reported an overall improvement in their condition.

5 Mar 2015

Dengue fever circulating in urban areas of West Africa

Misdiagnosis of febrile illnesses as malaria is a continuing problem in Africa. A new study shows that in Ghana, dengue fever is circulating in urban areas and going undiagnosed. The authors of the study hope to use the findings to launch a widespread initiative to better understand acute undifferentiated febrile illnesses in West Africa.

3 Mar 2015

FDA approves LILETTA (levonorgestrel-releasing intrauterine system) to prevent pregnancy

Actavis plc, a leading global specialty pharmaceutical company, and Medicines360, a nonprofit women's health pharmaceutical company, today announced the approval of LILETTA (levonorgestrel-releasing intrauterine system) by the U.S. Food and Drug Administration for use by women to prevent pregnancy for up to three years.

27 Feb 2015

Boehringer Ingelheim presents Phase III data for tiotropium at 2015 AAAAI Annual Meeting

Boehringer Ingelheim today presented data on investigational tiotropium delivered via Respimat inhaler from five Phase III trials from the UniTinA-asthma program at the 2015 American Academy of Allergy, Asthma & Immunology Annual Meeting in Houston, Texas.

24 Feb 2015

Virginia Tech biochemists identify potential drug target against sleeping sickness

Virginia Tech biochemists are trying to deliver a stern wake-up call to the parasite that causes sleeping sickness.

24 Feb 2015

Virus that causes chicken pox and shingles linked to giant cell arteritis

A new study developed at the University of Colorado School of Medicine at the Anschutz Medical Campus links the virus that causes chicken pox and shingles to a condition that inflames blood vessels on the temples and scalp in the elderly, called giant cell arteritis.

20 Feb 2015

New study links chicken pox and shingles virus to giant cell arteritis in elderly

A new study links the virus that causes chicken pox and shingles to a condition that inflames blood vessels on the temples and scalp in the elderly, called giant cell arteritis. The study is published in the February 18, 2015, online issue of Neurology, the medical journal of the American Academy of Neurology. The condition can cause sudden blindness or stroke and can be life-threatening.

19 Feb 2015

Hospira announces launch of first biosimilar monoclonal antibody in Europe

Hospira, Inc., a world leader in the development of biosimilar therapies, today announced the launch of the first biosimilar monoclonal antibody (mAb), Inflectra (infliximab), in major European markets.

16 Feb 2015

$Eisai announces FDA approval of LENVIMA (lenvatinib) for treatment of RAI-refractory DTC$

Eisai announces FDA approval of LENVIMA (lenvatinib) for treatment of RAI-refractory DTC

Eisai Inc. announced today that the U.S. Food and Drug Administration approved the company's receptor tyrosine kinase inhibitor LENVIMA (lenvatinib) for the treatment of locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer (RAI-R DTC).

13 Feb 2015

Elusys presents positive results of obiltoxaximab for treating inhalational anthrax, post-exposure prophylaxis

Elusys Therapeutics, Inc. (Elusys), a biopharmaceutical company developing antibody therapies to treat infectious disease, presented data demonstrating that obiltoxaximab (ETI-204) demonstrated a statistically significant survival benefit across a range of disease severity in animal model studies assessing treatment of inhalational anthrax, as well as effectiveness in post-exposure prophylaxis.

13 Feb 2015

Tips to help manage migraine in children

Although we may think of migraine as a disease of adults, it can also affect children of all ages. Some studies show migraine affects 6% of children and up to 28% of adolescents ages 15-17. To assist parents whose children suffer from migraine, and to help the children themselves, the American Migraine Foundation and its Chair, David W. Dodick, MD, FRCP (C) are offering a number of tips to help manage childhood migraine and minimize its impact.

12 Feb 2015

Headache News and Research

Latest Headache News and Research

Study finds no added benefit from sipuleucel-T in men with metastatic prostate cancer

AAPM announces recipients of 2015 Pain Medicine Fellowship Excellence Award

Cosentyx (secukinumab) safe, effective for treating psoriasis patients

Daiichi Sankyo signs co-commercialization agreement with AstraZeneca for MOVANTIK (naloxegol)

Endo announces commercial availability of NATESTO nasal gel for men with hypogonadism

Egalet announces net revenues of $1.9 million for 2014

Meta-analysis finds that high dose zinc acetate lozenges may help reduce duration of cold symptoms

New device can detect cyanide exposure within 70 seconds

FDA approves Astellas' CRESEMBA for treatment of invasive aspergillosis, invasive mucormycosis

electroCore’s gammaCore device effective in helping patients prevent, treat cluster headache

Dengue fever circulating in urban areas of West Africa

FDA approves LILETTA (levonorgestrel-releasing intrauterine system) to prevent pregnancy

Boehringer Ingelheim presents Phase III data for tiotropium at 2015 AAAAI Annual Meeting

Virginia Tech biochemists identify potential drug target against sleeping sickness

Virus that causes chicken pox and shingles linked to giant cell arteritis

New study links chicken pox and shingles virus to giant cell arteritis in elderly

Hospira announces launch of first biosimilar monoclonal antibody in Europe

Eisai announces FDA approval of LENVIMA (lenvatinib) for treatment of RAI-refractory DTC

Elusys presents positive results of obiltoxaximab for treating inhalational anthrax, post-exposure prophylaxis

Tips to help manage migraine in children

Innovation in neuroscience drug discovery - eBook eBook

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Headache News and Research

Latest Headache News and Research

Innovation in neuroscience drug discovery - eBook eBook

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Newsletters you may be interested in